Pharmacy benefit managers (PBMs) routinely update their provider manuals at year-end. While revisions to the terms and conditions of provider manuals sometimes implement changes that materially alter pharmacy participation, a newly added provision in the 2026 OptumRx Provider Manual could carry significant, system‑wide implications for pharmacies across its networks beginning in 2026. In this Pharmacy Alert, Frier Levitt attorneys explain the significance of this recent revision, and what this means for pharmacies, potential legal exposure, operational challenges and how to prepare.
Understanding the Revision
While previous editions of its provider manual have been silent regarding the volume of certain drug products dispensed by providers, the 2026 OptumRx Provider Manual now states that “Network Pharmacy Providers without specific arrangements previously approved by Administrator shall not have over 25% of their total claim submissions and/or amount paid related to Optum Rx members attributed to a single therapeutic class.”
In simpler terms, the volume of prescriptions for any one therapeutic class may not make up more than 25% of the total amount of claims submitted by participating providers, nor may the amounts reimbursed to a pharmacy for prescriptions of any one therapeutic class make up for than 25% of its total reimbursements.
In response, OptumRx may defend this restriction as a tool to detect outlier patterns indicative of suspicious dispensing and potential fraud, particularly in therapeutic classes historically associated with abuse, diversion, or inappropriate utilization. While OptumRx will likely take the position that these kinds of rules are not only reasonable, but necessary to prevent fraud, waste and abuse, the truth is that these types of arbitrary restrictions bear little, if any, empirically grounded relationship to the identification or prevention of fraud or misconduct. This is a result of type of practical realities of the practice of pharmacy which are too often not considered in PBM’s decision making.
Practical Implications on Provider Participation
In the abstract, violation of this term may seem easy enough to prevent – just make sure that your pharmacy practice does not specialize or concentrate too heavily on any one therapeutic area. In practice however, the unworkable nature of such a condition becomes apparent. This is due to the fact that volume of prescriptions and types of prescriptions fulfilled by pharmacies are typically driven by factors far outside their control. As an example, patient mix, geographic and demographic factors, physician prescribing patterns, and legitimate care model (i.e. pharmacies serving populations with concentrated clinical needs) necessarily affect the types of prescriptions they receive and therefore, fill. This is even more complicated when one also considers existence of state-specific regulations which statutorily prohibit pharmacists from refusing to fill certain prescriptions. Therefore, a pharmacy may naturally see a higher volume of prescriptions in certain therapeutic areas without any strategic intent to specialize, based solely on whether or not they happen to be located in a college-town with a high concentration of twenty-somethings or in a plaza that happens to be located across the street from a pain-management clinic.
Action Steps for Pharmacies Before 2026
As we get closer to the new year, pharmacies should prepare for OptumRx’s new rule to take effect. While this type of restriction is new for OptumRx, it is far from new to Frier Levitt attorneys, who have seen the result of similar therapeutic caps and prohibitions by other major PBMs firsthand. Accordingly, pharmacies should consider doing the following proactive steps ahead of 2026.
- Review your own dispensing history: Based on your pharmacy’s recent dispensing history, identify any patterns or trends by therapeutic class. Analyze your recent dispensing history by therapeutic class to understand where your pharmacy stands relative to the 25% threshold.
- Explore “Specific Arrangements” Early: Consider entering into one of the “specific arrangements” referenced in the revision to avoid potential violations all together.
- Identify the cause of dispensing trends and patterns: Make sure that you are able to provide reasons that your pharmacy may have a larger volume of certain types of prescription than other similarly situated pharmacies. If your dispensing patterns are driven by legitimate population needs, geography, or prescriber patterns, document these factors clearly to support any audit responses.
- Be prepared for higher scrutiny: Expect OptumRx to use this new policy to perform more audits, or make general inquiries regarding their dispensing patterns. Therefore, pharmacies should make sure they are responsive and prepare to provide prompt responses.
How Frier Levitt Can Help
If you are concerned about OptumRx’s newly codified therapeutic-class limit, or any other PBM provider manual updates and how they impact your pharmacy, Frier Levitt can help. Contact us to speak with an attorney today.
